Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) Products under Development by Stage of Development | 8 | 1 |
| Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) Products under Development by Therapy Area | 9 | 1 |
| Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) Products under Development by Indication | 10 | 1 |
| Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) Products under Development by Companies | 13 | 2 |
| Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) Therapeutics Assessment | 15 | 4 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 1 |
| Assessment by Molecule Type | 18 | 1 |
| Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) Companies Involved in Therapeutics Development | 19 | 4 |
| Albireo AB | 19 | 1 |
| CJ HealthCare Corp. | 20 | 1 |
| GlaxoSmithKline Plc | 21 | 1 |
| Shire Plc | 22 | 1 |
| Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) Drug Profiles | 23 | 13 |
| A-4250 Drug Profile | 23 | 2 |
| CJ-14199 Drug Profile | 25 | 1 |
| Drug to Inhibit IBAT for Liver and Metabolic Diseases Drug Profile | 26 | 1 |
| elobixibat Drug Profile | 27 | 2 |
| GSK-2330672 Drug Profile | 29 | 1 |
| maralixibat chloride Drug Profile | 30 | 3 |
| SC-435 Drug Profile | 33 | 1 |
| volixibat potassium Drug Profile | 34 | 2 |
| Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) Dormant Projects | 36 | 1 |
| Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) Featured News &Press Releases | 37 | 12 |
| Jul 29, 2016: Shire SHP626 (Volixibat) Receives FDA Fast Track Designation for an Investigational Treatment for Adults Who Have Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis | 37 | 1 |
| Jun 13, 2016: Shire Receives FDA Breakthrough Therapy Designation for Investigational Product SHP625 for Rare Gastrointestinal Condition | 37 | 1 |
| Nov 12, 2015: Albireo to Present A4250 Clinical Data at the 2015 AASLD Annual Meeting | 38 | 1 |
| Nov 10, 2015: Albireo Announces the Initiation in Japan of a Phase 3 Clinical Trial of Elobixibat in Chronic Constipation by Ajinomoto Pharmaceuticals | 38 | 1 |
| Apr 09, 2015: Shire Reports Topline Results from First of Three Placebo-Controlled Phase 2 Studies of SHP625 (LUM001) in Children with Alagille Syndrome | 39 | 1 |
| Feb 05, 2015: Initiation of a Phase II Trial for A4250, the Company s Lead Compound for Cholestatic Liver Diseases and NASH | 40 | 1 |
| May 09, 2014: Lumena Pharmaceuticals Now Dosing Patients in the INDIGO Phase 2 Clinical Trial of LUM001 in Pediatric Patients with Progressive Familial Intrahepatic Cholestasis | 40 | 1 |
| Apr 11, 2014: Albireo s Lead Compound in Cholestatic Liver Diseases, A4250, Protects Against Bile Acid-Mediated Cholestatic Liver Injury in Mice | 41 | 2 |
| Nov 05, 2013: Inhibition of ASBT Improves Liver Function in an Animal Model of Cholestatic Liver Disease | 43 | 1 |
| Oct 29, 2013: Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis | 44 | 1 |
| Sep 26, 2013: Lumena Pharmaceuticals Launches Global Clinical Program to Evaluate Safety and Efficacy of LUM001 in Children with Alagille Syndrome | 45 | 1 |
| Sep 26, 2013: Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food &Drug Administration for LUM001 in Four Rare Liver Diseases | 46 | 1 |
| May 02, 2013: Ferring Pharma Begins Phase III Trials Of Elobixibat For Chronic Idiopathic Constipation | 47 | 1 |
| Nov 08, 2012: Albireo Receives Orphan Drug Designation For A4250 From FDA For Treatment Of Progressive Familial Intrahepatic Cholestasis And For Primary Biliary Cirrhosis | 47 | 2 |
| Appendix | 49 | 2 |
| Methodology | 49 | 1 |
| Coverage | 49 | 1 |
| Secondary Research | 49 | 1 |
| Primary Research | 49 | 1 |
| Expert Panel Validation | 49 | 1 |
| Contact Us | 49 | 1 |
| Disclaimer | 50 | 1 |
